KOSELUGO Market Summary

Key Factors Driving KOSELUGO Growth

1. First-in-Class Position in NF1-Associated Plexiform Neurofibromas

KOSELUGO became the first FDA-approved therapy specifically indicated for pediatric patients with NF1-associated symptomatic, inoperable PN, addressing a significant unmet need where surgery is often difficult and recurrence rates are high. Historically, treatment options were limited primarily to surgery and supportive care, giving KOSELUGO a strong competitive foundation and established physician familiarity.

2. Expansion of the Treatable Patient Population

Regulatory label expansions are materially increasing the addressable market. In September 2025, the FDA approved KOSELUGO granules and capsules for children as young as 1 year old, extending treatment beyond the previous ≥2-year-old population. In November 2025, the FDA further approved KOSELUGO for adults with symptomatic, inoperable PN, creating a new commercial opportunity beyond pediatric patients.

3. Large Unmet Need and Chronic Disease Management

NF1 is a lifelong genetic disorder, and approximately 30–50% of NF1 patients develop plexiform neurofibromas during their lifetime. These tumors can cause pain, disfigurement, neurological impairment, and functional limitations. Because patients often require long-term therapy and monitoring, KOSELUGO benefits from durable treatment duration and recurring revenue potential.

4. Strong Real-World Adoption and Revenue Momentum

AstraZeneca reported that KOSELUGO revenue grew approximately 97% in 2024, making it one of the fastest-growing products within the company's Rare Disease portfolio. This growth reflects increasing physician awareness, broader reimbursement coverage, and continued penetration in specialized NF1 treatment centers.

5. Improved Diagnosis and Referral Networks

Earlier genetic testing, increased awareness among pediatric neurologists and oncologists, and the growth of specialized NF1 centers are improving diagnosis rates and patient referrals. Since many patients are diagnosed during childhood and require long-term disease management, earlier identification directly supports treatment initiation and long-term persistence. The FDA's approval in younger children further strengthens this trend.

6. Additional Growth from Adult NF1 Market Penetration

The adult NF1-PN population represents a substantial untapped opportunity. The 2025 adult approval was supported by the KOMET study and is expected to accelerate uptake among patients who previously relied on off-label access or observation. Adult adoption should become an increasingly important contributor to sales growth over the next several years.

KOSELUGO Recent Developments

In November 2025, Alexion, AstraZeneca Rare Disease’s Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in the US for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

“KOSELUGO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of KOSELUGO for approved indication like Neurofibromatosis 1; as well as potential indication like Glioma, Biliary cancer, Colorectal cancer, Gastric cancer, Histiocytosis, Neurofibromatosis 2, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, Solid tumours, and Uveal melanoma in the 7MM. A detailed picture of KOSELUGO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the KOSELUGO for approved and potential indications. The KOSELUGO market report provides insights about KOSELUGO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current KOSELUGO performance, future market assessments inclusive of the KOSELUGO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of KOSELUGO sales forecasts, along with factors driving its market.

KOSELUGO Drug Summary

KOSELUGO (selumetinib) is an oral, selective inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) developed by AstraZeneca and approved for the treatment of pediatric patients aged 2 years and older with symptomatic, inoperable plexiform neurofibromas associated with Neurofibromatosis Type 1 (NF1). By targeting the RAS/RAF/MEK/ERK signaling pathway, which is frequently overactivated in NF1-related tumors, KOSELUGO helps reduce tumor volume and improve associated symptoms such as pain, disfigurement, and functional impairment. The drug is administered orally as capsules, typically taken twice daily on an empty stomach, and was the first therapy specifically approved for NF1-associated plexiform neurofibromas. Clinical studies demonstrated significant and durable tumor shrinkage in a substantial proportion of treated patients, establishing KOSELUGO as a major advancement in the management of this rare genetic disorder. The report provides KOSELUGO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the KOSELUGO Market Report

The report provides insights into:

• A comprehensive product overview including the KOSELUGO MoA, description, dosage and administration, research and development activities in approved indications like Neurofibromatosis 1; as well as potential indication like Glioma, Biliary cancer, Colorectal cancer, Gastric cancer, Histiocytosis, Neurofibromatosis 2, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, Solid tumours, and Uveal melanoma.
• Elaborated details on KOSELUGO regulatory milestones and other development activities have been provided in KOSELUGO market report.
• The report also highlights KOSELUGO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The KOSELUGO market report also covers the patents information, generic entry and impact on cost cut.
• The KOSELUGO market report contains current and forecasted KOSELUGO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The KOSELUGO market report also features the SWOT analysis with analyst views for KOSELUGO in approved and potential indications.

Methodology

The KOSELUGO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KOSELUGO Analytical Perspective by DelveInsight

• In-depth KOSELUGO Market Assessment

This KOSELUGO sales market forecast report provides a detailed market assessment of KOSELUGO for approved indication like Neurofibromatosis 1; as well as potential indication like Glioma, Biliary cancer, Colorectal cancer, Gastric cancer, Histiocytosis, Neurofibromatosis 2, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, Solid tumours, and Uveal melanoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted KOSELUGO sales data uptil 2034.

• KOSELUGO Clinical Assessment

The KOSELUGO market report provides the clinical trials information of KOSELUGO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

KOSELUGO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

KOSELUGO Market Potential & Revenue Forecast

• Projected market size for the KOSELUGO and its key indications
• Estimated KOSELUGO sales potential (KOSELUGO peak sales forecasts)
• KOSELUGO Pricing strategies and reimbursement landscape

KOSELUGO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• KOSELUGO Market positioning compared to existing treatments
• KOSELUGO Strengths & weaknesses relative to competitors

KOSELUGO Regulatory & Commercial Milestones

• KOSELUGO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

KOSELUGO Clinical Differentiation

• KOSELUGO Efficacy & safety advantages over existing drugs
• KOSELUGO Unique selling points

KOSELUGO Market Report Highlights

• In the coming years, the KOSELUGO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The KOSELUGO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KOSELUGO’s dominance.
• Other emerging products for Neurofibromatosis 1; as well as potential indication like Glioma, Biliary cancer, Colorectal cancer, Gastric cancer, Histiocytosis, Neurofibromatosis 2, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, Solid tumours, and Uveal melanoma are expected to give tough market competition to KOSELUGO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KOSELUGO in approved and potential indications.
• Analyse KOSELUGO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted KOSELUGO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of KOSELUGO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of KOSELUGO? How strong is KOSELUGO’s clinical and commercial performance?
• What is KOSELUGO’s clinical trial status in each individual indications such as Neurofibromatosis 1; as well as potential indication like Glioma, Biliary cancer, Colorectal cancer, Gastric cancer, Histiocytosis, Neurofibromatosis 2, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, Solid tumours, and Uveal melanoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KOSELUGO Manufacturers?
• What are the key designations that have been granted to KOSELUGO for approved and potential indications? How are they going to impact KOSELUGO’s penetration in various geographies?
• What is the current and forecasted KOSELUGO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of KOSELUGO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to KOSELUGO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is KOSELUGO? What is the duration of therapy and what are the geographical variations in cost per patient?